glioblastoma
QV Bioelectronics secures £4.5m in funding for brain cancer therapy development
February 3, 2026Research and Development Oncology, QV Bioelectronics, glioblastoma
QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it has received £4.5m in funding …
Tracon shares data from phase 2 trial for glioblastoma treatment
June 12, 2024Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …
FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma
August 3, 2023Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma
ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …
Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows
March 6, 2020Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma
Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …
MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows
August 9, 2019Medical Communications MS, brain cancer, glioblastoma, oncology, pharma
The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure
March 9, 2018Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure
Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …
ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma
September 25, 2015Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma
ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …
Merck KGaA readies phase III brain cancer trial
June 13, 2011Research and Development Merck KGaA, brain cancer, cilengitide, glioblastoma
Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …
Brain cancer vaccine to move into phase III
November 24, 2010Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma
Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
